

Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation

S. Chung,^{*,†} B.-S. Shin,[†] E. Hedlund,^{*,†,‡} J. Pruszek,^{*,‡} A. Ferree,^{*,‡} Un Jung Kang,[§] Ole Isacson^{*,‡} and Kwang-Soo Kim^{*,†}

^{*}Udall Parkinson's Disease Research Center of Excellence, McLean Hospital, Belmont, MA, USA

[†]Molecular Neurobiology Laboratories, Harvard Medical School, Belmont, MA, USA

[‡]Neuroregeneration Laboratories, McLean Hospital/Harvard Medical School, Belmont, Massachusetts, USA

[§]Department of Neurology, The University of Chicago, Chicago, Illinois, USA

Abstract

Because of their ability to proliferate and to differentiate into diverse cell types, embryonic stem (ES) cells are a potential source of cells for transplantation therapy of various diseases, including Parkinson's disease. A critical issue for this potential therapy is the elimination of undifferentiated cells that, even in low numbers, could result in teratoma formation in the host brain. We hypothesize that an efficient solution would consist of purifying the desired cell types, such as neural precursors, prior to transplantation. To test this hypothesis, we differentiated sox1-green fluorescent protein (GFP) knock-in ES cells *in vitro*, purified neural precursor cells by fluorescence-activated cell sorting (FACS), and characterized the purified cells *in vitro* as well as *in vivo*. Immunocytofluorescence and RT-PCR analyses showed that this genetic purification procedure efficiently removed undifferentiated pluripotent stem cells. Furthermore, when differentiated into mature neurons *in vitro*, the purified GFP⁺ cell population generated enriched

neuronal populations, whereas the GFP⁻ population generated much fewer neurons. When treated with dopaminergic inducing signals such as sonic hedgehog (SHH) and fibroblast growth factor-8 (FGF8), FACS-purified neural precursor cells responded to these molecules and generated dopaminergic neurons as well as other neural subtypes. When transplanted, the GFP⁺ cell population generated well contained grafts containing dopaminergic neurons, whereas the GFP⁻ population generated significantly larger grafts (about 20-fold) and frequent tumor-related deaths in the transplanted animals. Taken together, our results demonstrate that genetic purification of neural precursor cells using FACS isolation can effectively remove unwanted proliferating cell types and avoid tumor formation after transplantation.

Keywords: embryonic stem cell, fluorescence-activated cell sorting, neural precursors, sox1, transplantation.

J. Neurochem. (2006) **97**, 1467–1480.

Embryonic stem (ES) cells are derived from the inner cell mass of pre-implantation mouse embryos (Evans and Kaufman 1981; Martin 1981) and represent pluripotent cells that can give rise to most cell types (Nagy *et al.* 1990, 1993). ES cells can be permanently maintained *in vitro* as pluripotent cells and, upon exposure to appropriate differentiation signals, can differentiate into a vast range of cell lineages (Smith 1991; Desbaillets *et al.* 2000). These unique properties make ES cells a useful tool for analyzing critical steps of cell development using both animal models and *in vitro* differentiation culture systems (Hooper *et al.* 1987; Thomas and Capecchi 1987; Nagy *et al.* 1990, 1993; Dinsmore *et al.* 1996; Wutz and Jaenisch 2000). In

addition, the capacity of ES cells to generate terminally-differentiated cell types provides a potentially unlimited resource for cell replacement therapy (Dinsmore *et al.* 1996;

Received October 25, 2005; revised manuscript received January 23, 2006; accepted January 25, 2006.

Address correspondence and reprint requests to Kwang-Soo Kim, Ph.D., MRC 216, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02178, USA. E-mail: kskim@mclean.harvard.edu

Abbreviations used: bFGF, basic fibroblast growth factor; DAT, dopamine transporter; EB, embryoid body; ES, embryonic stem cell; FACS, fluorescence-activated cell sorting; FN, fibronectin; GFP, green fluorescent protein; 5-HT, serotonin; NDS, normal donkey serum; NP, neural precursor; PBS, phosphate-buffered saline; PCA, perchloric acid; PD, Parkinson's disease; PLO, poly L-ornithine; VM, ventral mesencephalon.

Brustle *et al.* 1999; Lumelsky *et al.* 2001; Bjorklund *et al.* 2002).

We have previously shown that *in vivo* grafting of mouse ES (mES) cells could ameliorate behavioral deficits in rodent models of Parkinson's disease (PD) by generating mature dopaminergic (DA) neurons in the brain (Bjorklund *et al.* 2002). In addition, we and others have shown that mature DA neurons can be efficiently generated *in vitro* by genetic modification of mES cells with the transcription factor, Nurr1 (Chung *et al.* 2002; Kim *et al.* 2002). However, we and others observed that grafting *in vitro*-differentiated ES cells does not eliminate abnormal and disruptive growth post-transplantation (data not shown; Arnhold *et al.* 2004). Thus, for clinical application of ES-derived cells for transplantation therapy, it is essential to safeguard from any potential tumor formation derived from the grafted cells. It is therefore important to establish a procedure that can purify only the desired cell type and thus avoid post-grafting tumor formation.

Sox1 is a member of a family of transcription factors containing the HMG-box DNA binding domain (Kamachi *et al.* 2000). Three members of the Sox family (Sox1, Sox2 and Sox3) are expressed in the neuroectoderm. While expression of Sox2 and Sox3 starts at the pre-implantation and the epiblast stage, respectively (Pevny *et al.* 1998), the onset of Sox1 expression correlates with the formation of neural plate, and its expression is down-regulated as neural cells exit the cell cycle and differentiate (Uwanogho *et al.* 1995; Pevny *et al.* 1998; Wood and Episkopou 1999). These observations mean that Sox1 is an ideal marker for neural precursor (NP) cells. In addition, Sox1 has been shown to be critical in maintaining NPs at the undifferentiated state by counteracting the activity of proneural proteins and inhibiting neurogenesis (Bylund *et al.* 2003). In Sox1-green fluorescent protein (GFP) knock-in ES cells, GFP is specifically expressed by NP cells both *in vivo* and *in vitro* (Ying *et al.* 2003), thus making fluorescence-activated cell sorting (FACS) purification of NPs possible.

To test whether purification of NP cells removes tumor-forming cells, we purified ES cell-derived NPs using sox1-GFP knock-in ES cells by FACS, and characterized GFP⁺ versus GFP⁻ cells both *in vitro* and *in vivo*. Here, we show that sorting GFP⁺ cells greatly enriched the NP population and efficiently removed stage specific embryonic antigen-1 (SSEA1⁺) pluripotent stem cells from the NP population. Furthermore, transplantation of sorted cells did not generate tumors, strongly suggesting that this genetic procedure could play an important role in future cell therapy by efficiently removing tumor-forming cells.

Materials and methods

ES cell culture and *in vitro* differentiation

Mouse ES cell lines 46C (sox1-GFP knock-in ES cells, a kind gift from Dr Smith) (Ying *et al.* 2003) and J1 were maintained as

described previously (Deacon *et al.* 1998). Briefly, undifferentiated ES cells were cultured on gelatin-coated dishes in Dulbecco's modified minimal essential medium (DMEM; Life Technologies, Rockville, MD, USA) supplemented with 2 mM L-glutamine (Life Technologies), 0.001% β -mercaptoethanol (Life Technologies), 1 \times non-essential amino acids (Life Technologies), 10% donor horse serum (Sigma, St. Louis, MO, USA) and 2000 U/mL human recombinant leukemia inhibitory factor (LIF; R & D Systems, Minneapolis, MN, USA).

ES cells were differentiated into embryoid bodies (EBs) on non-adherent bacterial dishes (Fisher Scientific, Pittsburgh, PA, USA) for 4 days in the above medium without LIF and exchanging horse serum with 10% fetal bovine serum (Hyclone, Logan, UT, USA). EBs were then plated onto an adhesive tissue culture surface (Fisher Scientific). After 24 h in culture, selection of neuronal precursor cells was initiated in serum-free insulin, transferin, selenium and fibronectin (ITSFn) media (Okabe *et al.* 1996). After 10 days of selection, cells were trypsinized and nestin⁺ neuronal precursors were plated onto poly L-ornithine- (PLO; 15 μ g/mL; Sigma) and fibronectin (FN; 1 μ g/mL; Sigma)-coated plates in NP medium [NP medium; N2 medium (Johe *et al.* 1996) supplemented with 1 μ g/mL laminin (Sigma) and 10 ng/mL basic fibroblast growth factor (bFGF) (R & D Systems)]. After 2 days' expansion of nestin⁺ neuronal precursors, cells were trypsinized and subjected to FACS. Subsequently, 1.5 \times 10⁶ sorted cells/cm² were plated onto PLO/FN-coated 6 wells, expanded in the presence of 500 ng/mL N-terminal fragment of sonic hedgehog (R & D Systems) and 100 ng/mL fibroblast growth factor-8 (FGF-8) (R & D Systems) for 4 days. Cells were either harvested for transplantation or induced to differentiate by removal of bFGF in the presence of 200 μ M ascorbic acid (Sigma) (Lee *et al.* 2000; Chung *et al.* 2002). Cells were eventually fixed 10 days after starting neuronal differentiation.

Fluorescence-activated cell sorting

In vitro-differentiated NP cells derived from 46C ES cells were trypsinized after expansion for 2 days as described above, suspended in phosphate-buffered saline (PBS) and subjected to FACS using the FACSARIA (BD Biosciences, San Jose, CA, USA) to purify GFP⁺ and GFP⁻ cell populations. The samples were first gated on forward and side-light scatter, and subsequently, within this population based on GFP expression. Non-GFP-expressing J1 cells that had been similarly differentiated were used as negative control for background fluorescence.

Immunocytochemistry and cell counting

For immunofluorescence staining, cells were fixed in 4% formaldehyde (Electron Microscopy Sciences, Ft. Washington, PA, USA) for 30 min, rinsed with PBS and then incubated with blocking buffer (PBS, 10% normal donkey serum; NDS) for 10 min. Cells were then incubated overnight at 4°C with primary antibodies diluted in PBS containing 2% NDS. The following primary antibodies were used: mouse anti-nestin (Rat401; Developmental Studies Hybridoma Bank, Iowa City, IA, USA; 1 μ g/mL), rabbit anti- β -tubulin (Covance, Princeton, NJ, USA; 1 : 2000), mouse anti-Engrailed-1 (En-1; 4G11; Developmental Studies Hybridoma Bank; 1 : 40), sheep anti-tyrosine hydroxylase (TH) (Pel-Freeze, Rogers, AR, USA; 1 : 200), sheep anti-aromatic L-amino acid

decarboxylase (AADC; Chemicon, Temecula, CA, USA; 1 : 200), rat anti-dopamine transporter (DAT; Chemicon; 1 : 2000), mouse anti-SSEA1 (Developmental Studies Hybridoma Bank; 1 µg/mL), mouse anti-neuron-specific nuclear (NeuN) (Chemicon; 1 : 100), rabbit anti-serotonin (5-HT; DiaSorin, Stillwater, MN, USA; 1 : 2500), rabbit anti-gamma aminobutyric acid (GABA; Sigma; 1 : 1000), rabbit anti-glutamate (Sigma; 1 : 200), rabbit anti-glial fibrillary acidic protein (GFAP; Dako, Denmark; 1 : 500), rabbit anti-Ki67 (Novocastra, Newcastle upon Tyne, UK; 1 : 2000) and mouse anti-galactocerebroside (galC) antibody (Chemicon; 1 : 200). After additional rinsing in PBS, the coverslips were incubated in fluorescent-labeled secondary antibodies (Cy2- or rhodamine red-X-labeled donkey IgG; Jackson ImmunoResearch, West Grove, PA, USA) in PBS with 2% NDS for 30 min at 21°C. After rinsing for 3 × 10 min in PBS, sections were counterstained using 5 µg/mL Hoechst, then mounted onto slides in Gel/Mount (Biomedica Corp., Foster City, CA, USA). Coverslips were examined using a Leica (Wetzlar, Germany) TCS/NT confocal microscope equipped with krypton, krypton/argon and helium lasers.

Cell density was determined by counting the numbers of cells with marker gene expression per field at 40× magnification using a Zeiss (Thornwood, NY, USA) Axioplan I fluorescent microscope. Ten visual fields were randomly selected and counted for each sample. Numbers presented in figures represent the average percentage and SEM from three samples from independent experiments. For statistical analysis, we used STATVIEW software (SAS Institute, Cary, NC, USA) and performed ANOVA with an alpha level of 0.05 to determine possible statistical differences between group means. When significant differences were found, post-hoc analysis was performed using Fisher's protected least significant difference (PLSD) (alpha = 0.05).

Semi-quantitative RT-PCR analysis

Total RNA from plated cells at different stages during the differentiation protocol was prepared using TriReagent (Sigma) followed by treatment with DNase I (Ambion, Austin, TX, USA). For RT-PCR analysis, we transcribed 5 µg RNA into cDNA using oligo (dT) primers, according to the SuperScript Preamplication Kit (Life Technologies). The cDNA was then analyzed by PCR using the following primers: β-actin: 5'-GGCATTGTGATG-GACTCCGG-3', 5'-TGCCACAGGATTCCATACCC-3' (358 bp); Oct4: 5'-CTGAGGGCCAGGCAGGAGCACGAG-3', 5'-CTGTA-GGGAGGGCTTCGGGCACTT-3' (462 bp; Mitsui *et al.* 2003); nanog: 5'-AGGGTCTGCTACTGAGATGCTCTG-3', 5'-CAACC-ACTGGTTTTCTGCCACCG-3' (Mitsui *et al.* 2003); ERas: 5'-ACTGCCCTCATCAGACTGCTACT-3', 5'-CACTGCCTTGT-ACTCGGGTAGCTG-3' (Takahashi *et al.* 2003); Nestin: 5'-GGAG-TGTCGCTTAGAGGTGC-3', 5'-TCCAGAAAGCCAAAGAGAA-CCCCAAGATG-3', 5'-CCGTTAGCCCAGCCGTTGAC-3'; Bmi1: 5'-TTGCTGCTGGGCATCGTAAG-3', 5'-CCAATGGCTCCAAT-GAAGACC-3' (Molofsky *et al.* 2003).

PCR reactions were carried out in 1 × IN Reaction Buffer (Epicentre Technologies, Madison, WI, USA) containing 1.4 nM each primer and 2.5 U Taq I DNA polymerase (Promega, Madison, WI, USA). Samples were amplified in an Eppendorf Thermocycler (Brinkmann Instruments, Westbury, NY, USA) under the following conditions: denaturing step at 95°C, 40 s; annealing step at 60°C,

30 s; amplification step at 72°C, 1 min for 20–28 cycles and a final amplification step at 72°C, 10 min. For semi-quantitative PCR, cDNA templates were normalized by amplifying actin-specific transcripts.

Analysis of catecholamines

Differentiated ES cells or E12.5 ventral mesencephalon (VM) cells (stage 5 day 10) in 12-well plates were treated with 200 µL N3 medium supplemented with 50 mM KCl; the medium was collected after 30 min, followed by addition of perchloric acid (PCA) to a final concentration of 0.1 M PCA/0.1 mM EDTA. These de-proteinated samples were centrifuged and supernatant fluids were kept at –80° until further analysis. Samples were filtered through a 0.22 µm nylon filter (Osmonics, Inc., Trevose, PA, USA) and analyzed for their catecholamine content by reverse-phase HPLC using a Velosep RP-18 column (100 × 3.2 mm; Brownlee Laboratories, Wellesley, MA, USA) and an ESA Coulochem II electrochemical detector equipped with a 5014 analytical cell (ESA Biosciences, Inc., Chelmsford, MA, USA) as described (Wachtel *et al.* 1997). The mobile phase consisted of 0.1 M sodium phosphate buffer (pH 2.65), 0.1 mM EDTA, 0.4 mM sodium octyl sulfate and 9% (v/v) methanol. The flow rate of the mobile phase through the system was 0.8 mL/min. The guard cell potential was set at 330 mV. The potential of the first electrode in the analytical cell was set at 0 mV, the second at 310 mV. L-DOPA, dopamine, dihydroxyphenyl acetic acid (DOPAC) and homovanillic acid (HVA) were identified by retention time, and quantified based on peak height using the EZChrom Chromatography Data System (ESA Biosciences, Inc.). The limit of detection for all compounds was <1 pg. DA content of each sample was normalized with the amount of total cellular proteins. For protein measurement, after harvesting cells in 0.1 M PCA/0.1 mM EDTA, precipitates were resuspended in 10 mM potassium phosphate buffer with 0.2% triton-X, pH 7 and sonicated. The protein content was measured using the Bio-Rad Assay (Bio-Rad Laboratories, Hercules, CA, USA).

Transplantation analysis

GFP⁺ or GFP⁻ cell populations were trypsinized after 4 days' induction with SHH and FGF8, and resuspended at a density of 200 000 cells/µL. A 1 µL volume of cell suspension was grafted into the right striatum (from the bregma: AP +0.05, L –0.18, V –0.30, IB 9) of C57/BL6 mice (*n* = 11) (Charles River Breeding Laboratories, Wilmington, MA, USA). Prior to surgery, mice received an i.p. injection of acepromazine (3.3 mg/kg, PromAce, Fort Dodge, IA, USA) and atropine sulfate (0.2 mg/kg, Phoenix Pharmaceuticals, St. Joseph, MO, USA), followed by anesthesia with an i.p. injection of ketamine (60 mg/kg, PromAce) and xylazine (3 mg/kg, Phoenix Pharmaceuticals). Transplantation was performed using a 22-gauge, 10 µL Hamilton syringe and a Kopf stereotaxic frame (Kopf Instruments, Tujunga, CA, USA). Post-operative analgesia consisted of two s.c. injections of buprenorphine (0.032 mg/kg, Sigma) over 24 h. Eight weeks after transplantation, mice were killed with an i.p. overdose of pentobarbital (150 mg/kg, Sigma). Subsequently, mice were perfused intracardially with 100 mL heparin saline (0.1% heparin in 0.9% saline) followed by 200 mL paraformaldehyde (4% in PBS). Brains were post-fixed for 8 h, equilibrated in sucrose (20% in PBS), sectioned at 40 µm on a freezing microtome

(Microm, Waldorf, Germany) and collected in PBS. For histological analysis, sections were stained with antibodies against TH and NeuN (see above). Graft volumes were measured using an integrated Axioskop 2 microscope (Carl Zeiss, Thornwood, NY, USA) and StereoInvestigator image capture equipment and software (Microbright Field, Williston, VT, USA). To determine the total TH⁺ cell number within the GFP⁺ grafts, every sixth section was stained and counted.

Results

Sox1-GFP knock-in ES cells generate GFP⁺ cells that co-localize with nestin expression after *in vitro* differentiation and can generate dopaminergic neurons

Several lines (e.g. D3, J1 and R1) of mES cells have been shown to differentiate into NPs and then into dopaminergic neurons, using the five-stage *in vitro* differentiation method (Lee *et al.* 2000). We first tested whether the same method could be used for *in vitro* differentiation of Sox1-GFP knock-in ES cells. In brief, ES cells were differentiated *in vitro* as embryoid body (EB) cells for 4 days, then transferred to tissue culture plates and serum-free medium for selection of NP cells. At the ES and EB stages, neither endogenous Sox1 mRNA nor GFP expression was detected (data not shown). After 10 days of selection, cells were trypsinized and transferred into N2 medium containing bFGF for expansion of NP cells. At this stage, numerous GFP⁺ cells were generated (Fig. 1a). In addition to GFP expression, these GFP⁺ cells expressed another NP marker, nestin (Figs 1b and c). However, most of GFP⁺ cells did not overlap with more mature neural cell markers such as NeuN and GFAP, demonstrating the transient nature of GFP expression (Figs 1d–i). Overlap between GFP and mature neural cell markers in a few cells is likely due to the longer half life of GFP compared with endogenous sox1 (Pevny *et al.* 1998). When bFGF was removed from the medium to further differentiate these NP cells, a great number of Tuj1⁺ neurons were generated (Fig. 1j) that contained many dopaminergic neurons, as examined by TH immunocytofluorescence (Fig. 1j–l).

FACS efficiently enriches NP population and removes pluripotent stem cells

Next, we purified GFP⁺ NPs derived from sox1-GFP ES cells. Prior to FACS, sox1-GFP ES cells were differentiated to the NP stage and expanded in bFGF for 2 days. Cells were first gated using side and forward scatter to remove any cell debris and doublets. Then, cells were sorted and collected into GFP⁺ and GFP⁻ populations, as shown in Fig. 2(a). GFP non-expressing J1 cells were similarly differentiated and used as negative control to set up the gating. Sorted cells were immediately re-analyzed by FACS scan (Fig. 2b), which showed that 93.9% of sorted GFP⁺ cells fell within the GFP⁺ gate. Analysis by inverted microscope immediately




Fig. 1 *In vitro* differentiation of sox1-GFP knock-in ES cells. Sox1-GFP ES cells were differentiated as described in Materials and methods, fixed at the NP stage (a–i) or ND stage (j–l) and analyzed by immunocytofluorescence. Confocal microscopy at 40× magnification of representative fields is shown. Scale bar = 50 μm.

after sorting (Figs 2c and d) also showed that most of the cells sorted were GFP⁺. These analyses of purified cells demonstrated that the FACS procedure effectively purified NP cells expressing GFP. In addition, sorted cells were plated back on tissue culture plates and recovered/expanded for 4 more days in NP medium. Here, a recovery/expansion step after FACS was included to increase survival of the NPs to be used for further *in vitro* analyses, as well as for transplantation. The proportion of GFP⁺ cells was decreased during the *in vitro* differentiation of sorted cells. After 4 days of expansion (NP stage day 4), there were $68.02 \pm 6.56\%$ GFP⁺ cells out of the total cells. After induction of final differentiation by mitogen removal, the proportion of GFP⁺ cells further decreased to $27.18 \pm 3.54\%$ at early ND stage (ND day 5) and to $7.36 \pm 0.71\%$ GFP⁺ at later ND stage (ND stage day 10) (Fig. 2e).

As shown in Figs 3(a–p), in the GFP⁺ cell population after 4 days' expansion, GFP⁺ cells that co-express the neural precursor marker, nestin, were greatly enriched. These GFP⁺ cells showed a wide range of nestin expression, suggesting different stages of neural precursor and/or cellular variability. In contrast, the GFP⁻ population contained few GFP⁺ and




Fig. 2 Isolation of sox1-GFP-expressing NPs using FACS. (a) Sox1-GFP ES cells were differentiated to the NP stage, and GFP⁺ and GFP⁻ cell populations were isolated by FACS. J1 ES cells differentiated the same way were used as negative control. (b) FACS purification of Sox1-GFP precursors was re-analyzed after FACS purification to confirm purity. The black line represents FACS profile of J1 cells as a negative control and the green line represents the samples analyzed. Sox1-GFP⁺ cells were fixed 2 h after sorting and analyzed by bright field and fluorescent microscopy (c, d) for validation of sorting efficiency.

ciency. Scale bar = 50 μ m. (e) Sox1GFP⁺ cells were fixed at different time points during *in vitro* differentiation [4 days after FACS (NP d4), 5 days of neuronal differentiation stage (ND d5) and 10 days of neuronal differentiation stage (ND d10)]. Numbers of GFP⁺ cells and Hoechst⁺ cells were counted on multiple random fields for each sample, and the proportion of GFP⁺ cells was calculated by dividing the number of GFP⁺ cells by the number of Hoechst⁺ cells. Each group represents an average of three samples from each independent experiment.

nestin⁺ cells following the 4 days' *in vitro* recovery/expansion step after FACS sorting. Further immunocytofluorescence analysis showed that FACS efficiently removed cells expressing the pluripotent cell marker, SSEA1 (Figs 3q–v). These SSEA1⁺ cells, due to their avid proliferation capacity and potential to generate different cell types, are likely to generate large and disruptive grafts in the host brain. We next performed RT-PCR analysis to assess differential gene expression of these marker proteins. Consistent with our immunocytofluorescence analysis, mRNAs encoding NP

markers sox1 and nestin were highly enriched in the GFP⁺ cell population, while those encoding pluripotent stem cell markers (e.g. Oct4, Eras and nanog) were significantly enriched in the GFP⁻ cell population (Fig. 3w).

We further differentiated FACS-purified GFP⁺ and GFP⁻ cells *in vitro*, in serum-free medium, and analyzed them by immunocytofluorescence (Fig. 4). This analysis showed that the GFP⁻ population generated very few neuronal or astrocytic cells (Figs 4a–d). In sharp contrast, FACS-purified GFP⁺ cell populations efficiently generated Tuj1⁺ neuronal cells and




Fig. 3 NPs can be efficiently purified and pluripotent stem cells removed by FACS. GFP⁺ and GFP⁻ cells were fixed 4 days after FACS and analyzed by immunocytofluorescence using antibodies against nestin (a–p) or SSEA1 (q–v). Shown are representative fields using confocal microscopy at 40×. Scale bar = 50 μm. (w) Total RNAs were prepared from GFP⁻ and GFP⁺ cells at the NP stage after FACS and analyzed by RT-PCR analysis.

GFAP⁺ astrocytes (Figs 4e–h). Cell counting analysis showed that GFP⁻ and GFP⁺ cells generated $2.90 \pm 0.13\%$ and $44.29 \pm 7.93\%$ βIII-tubulin⁺ neurons per total cells, respectively (Fig. 4i). In addition, GFP⁻ and GFP⁺ cells generated $1.09 \pm 0.27\%$ and $22.94 \pm 2.07\%$ GFAP⁺ astrocytes per total cells, respectively (Fig. 4i). These results demonstrate that our procedure can effectively select ES-derived NP cells that

have differential potential to generate neural cell populations. We also performed immunocytofluorescence using GalC antibody. This analysis showed that a small number of oligodendrocytes was generated from sox1-GFP⁺ cells, but not at all from sox1-GFP⁻ cells (data not shown). Modification of our spontaneous differentiation procedure may be needed to for optimal generation of oligodendrocytes.




Fig. 4 FACS-purified NPs generate neural cell-enriched cell populations. (a–h) FACS-isolated GFP⁻ and GFP⁺ cells were fully differentiated, fixed at the ND stage and analyzed by immunocytofluorescence using antibodies against βIII-tubulin and GFAP. Slides were counterstained using Hoechst. Shown are representative fields using confocal microscopy at 40× magnification. Scale bar = 50 μm. (i) The numbers of βIII-tubulin⁺, GFAP⁺ and Hoechst⁺ cells from sox1-GFP⁻ and sox1-GFP⁺ cells were counted on multiple random fields per each sample, and the proportions of neurons and astrocytes were calculated

by dividing the numbers by the total number of Hoechst⁺ cells. Each group represents an average of three samples from each independent experiment. For neuronal phenotype, ANOVA revealed $F = 27.240$, $p < 0.05$. Fisher's PLSD post-hoc analysis was performed with a significance level of 0.05; *indicates significant difference from sox1-GFP⁻ cells. For astrocytic phenotype, ANOVA revealed $F = 99.536$, $p < 0.05$. Fisher's PLSD post hoc analysis was performed with a significance level of 0.05 ($n = 3$); *indicates significant difference from sox1-GFP⁻ cells.

FACS-purified NPs can generate dopaminergic neurons as well as other neural subtypes

To test the potential of FACS-purified NPs to generate midbrain dopaminergic lineages, we differentiated them *in vitro* and further analyzed them by immunocytofluorescence. As shown in Fig. 5(a–c), we found that many GFP⁺ cells also expressed the early midbrain marker, Engrailed 1 (En-1). After full differentiation (day 10 of the ND stage), some of these cells expressed the dopaminergic marker, TH (Figs 5d–f). These TH⁺ neurons, generated from FACS-purified NPs, also expressed other dopaminergic markers

such as dopa decarboxylase (DDC) (Figs 5g–i) and dopamine transporter (DAT) (Figs 5j–l). Cell counting analysis showed that sox1-GFP⁻ and sox1-GFP⁺ cells generated $0.69 \pm 0.22\%$ and $2.42 \pm 0.36\%$ TH⁺ neurons per total cells, respectively (Fig. 5m). Unexpectedly, when analyzed for DA neuronal phenotype among neurons, sox1-GFP⁻ cells generated a higher proportion of DA neurons compared with sox1-GFP⁺ cells, with sox1-GFP⁻ and sox1-GFP⁺ cells generating $19.44 \pm 6.02\%$ and $6.43 \pm 0.95\%$ TH⁺ neurons per total neurons, respectively (Fig. 5m). To test the functionality of these DA neurons, *in vitro*-differentiated cells were treated




Fig. 5 FACS-purified NPs can generate dopaminergic neurons. FACS-purified GFP⁺ cells were analyzed at the NP stage by immunocytofluorescence using an antibody against the early midbrain marker En-1 (a–c). FACS-purified GFP⁺ cells were fully differentiated and analyzed by immunocytofluorescence using antibodies against dopaminergic markers such as TH (d–f), DDC (g–i) and DAT (j–l). Shown are representative fields using confocal microscopy at 40× magnification. Scale bar = 50 μm. (m) Fully differentiated sox1-GFP⁺ cells and sox1-GFP⁻ cells were stained, using antibodies against βIII-tubulin and TH, and counterstained with Hoechst. The numbers of TH⁺, βIII-tubulin⁺ and Hoechst⁺ cells from sox1-GFP⁻ and sox1-GFP⁺ cells were counted in multiple random fields for each sample, and the proportions of DA neurons among the total number of neurons and total cells were calculated by dividing the numbers of DA neurons by the number of Hoechst⁺ cells. Each group represents an average of three samples from each independent experiment. For proportion of

TH⁺ cells among neurons, ANOVA revealed $F = 4.566$, $p < 0.05$. Fisher's PLSD post-hoc analysis was performed with a significance level of 0.05; *indicates significant difference from sox1-GFP⁻ cells. For the proportion of TH⁺ cells among total cells, ANOVA revealed $F = 17.364$, $p < 0.05$. Fisher's PLSD post-hoc analysis was performed with a significance level of 0.05; *indicates significant difference from sox1-GFP⁻ cells. (n) sox1-GFP⁺ cells and sox1-GFP⁻ cells, after full differentiation, released dopamine in response to membrane depolarization. GFP⁺ cells, GFP⁻ cells, a mixture of GFP⁺/GFP⁻ cells and mouse E12.5-derived primary DA cells (VM) were differentiated (stage 5 day 10) and treated with 50 mM KCl for 30 min, then the medium was collected and analyzed for dopamine content by HPLC. ANOVA revealed $F = 5.459$, $p < 0.05$. Fisher's PLSD post-hoc analysis was performed with a significance level of 0.05; *indicates significant difference from GFP⁻ and VM cells.

with 50 mM KCl for 30 min and the dopamine content of the medium was analyzed by HPLC. As shown in Fig. 5(n), these dopaminergic neurons originating from GFP⁻ and GFP⁺ cells released significant amounts of dopamine in response to membrane depolarization, with 2.96 ± 0.10 and 5.03 ± 0.72 pg/ μ g cellular proteins, respectively. Because of the unexpected observation that a large proportion of GFP⁻ cell-derived neurons are dopaminergic, even though very small numbers of neurons are generated from the GFP⁻ cell population, it might be possible that the GFP⁻ population may contain a DA inducing activity/signal. Thus, we mixed the GFP⁺ and GFP⁻ population after FACS and fully differentiated them *in vitro*. However, we could not detect any additive effect by mixing the GFP⁻ population with the GFP⁺

population, in terms of DA differentiation (4.69 ± 0.50 pg/ μ g cellular proteins; Fig. 5n). Primary dopaminergic neurons, derived from E12.5 mouse embryo VM, were cultured in the same way as the FACS sorted cells and used as a control for DA release; these released 3.06 ± 0.28 pg/ μ g cellular proteins in response to membrane depolarization (Fig. 5n).

We next tested whether sorted GFP⁺ cells could generate other neuronal subtypes. Immunocytofluorescent analyses of *in vitro*-differentiated GFP⁺ cells demonstrated that serotonergic (Figs 6a–c), GABAergic (Figs 6d–f) and glutamatergic neurons (Figs 6g–i) could be efficiently generated from these cell populations. Cell-counting analysis showed that the proportion of each subtype was $5.06 \pm 1.38\%$, $51.12 \pm 4.91\%$ and $26.77 \pm 2.04\%$ for serotonergic,





Fig. 6 FACS-purified NPs can generate other neural subtypes. FACS-purified GFP⁺ cells were fully differentiated and analyzed by immunocytofluorescence using antibodies against serotonin (a–c), GABA (d–f) and glutamate (g–i). Shown are representative fields using confocal microscopy at 40 \times magnification. Scale bar = 50 μ m. (j) sox1-GFP⁺ cells were fixed after neuronal differentiation stage (ND d10) and numbers of 5HT⁺, GABA⁺, glutamate⁺ and Hoechst⁺ cells were counted in multiple random fields per each sample. The proportion of each phenotype was calculated by dividing the cell numbers by the number of Hoechst⁺ cells. Each group represents an average of three samples from each independent experiment.



GABAergic and glutamatergic neurons, respectively (Fig. 6j). Taken together, these FACS-purified GFP⁺ cells appear to have the full developmental potential of authentic NP cells to differentiate into various neuronal subtypes and glial cell types.

Transplantation analysis of FACS-purified NPs

Based on the above *in vitro* data, we speculated that FACS-purified GFP⁺ or GFP⁻ cells may behave quite differently after grafting into the host brain. To address this hypothesis, we transplanted 200 000 GFP⁺ or GFP⁻ FACS-purified cells into the striatum of normal mice ($n = 11$). Grafts were analyzed 8 weeks post-transplantation. Six out of 11 mice transplanted with GFP⁻ cells succumbed to tumors before 8 weeks. Some of these mice were post-fixed and included in the histological analysis. GFP⁻ cells generated large and disruptive grafts, whereas GFP⁺ cells generated well contained grafts (Figs 7a and b). The presence of TH⁺ neurons in grafts from GFP⁺ cells was established by TH immunohistochemistry (Figs 7c and d). Sham-treated sides (contralateral to the grafted side) had only TH fibers in the striatum, but never TH cell bodies (Fig. 7e).

When total graft volume was measured, there was a significant difference between the sizes of GFP⁻ grafts and those of GFP⁺ grafts ($43.262 \pm 10.757 \text{ mm}^3$ vs. $2.758 \pm 1.962 \text{ mm}^3$; Fig. 7f). However, DA neuronal density within the grafts was significantly higher in GFP⁺ grafts compared with GFP⁻ grafts, with 103.22 ± 23.28 DA neurons/mm³ and 19.15 ± 3.18 DA neurons/mm³ for GFP⁺ and GFP⁻ grafts, respectively. Based on the high occurrence of SSEA⁺ cells only in the GFP⁻ population (Fig. 3), we speculate that the graft size differences may be due to the presence of highly proliferative pluripotent stem cells within the GFP⁻ cell population. Indeed, immunohistochemistry analysis confirmed the presence of SSEA1⁺ cell clusters in some GFP⁻ grafts even 8 weeks after transplantation (Fig. 7h). In contrast, no SSEA1⁺ cells were detected in the GFP⁺ grafts (Fig. 7i). Analysis of the presence of proliferating cells in the grafts showed that GFP⁻ grafts contained numerous Ki67⁺ cells 8 weeks after transplantation (Fig. 7j), whereas few such cells were found in GFP⁺ grafts (Fig. 7k). Cell-counting analysis of GFP⁺ grafts showed that they contained 198 ± 75.6 TH⁺ neurons per graft, and these TH neurons also co-expressed DDC and DAT (Fig. 7l–o).

Discussion

Neural stem/precursor cells can self-renew and maintain their potential to generate differentiated progenies such as neurons, astrocytes and oligodendrocytes (Seaberg and van der Kooy 2003). Thus, they represent both an excellent tool to study neural cells *in vitro* and a potential source of unlimited cells for cell replacement therapy of neurodegenerative

diseases. In order to use these differentiated neural cells therapeutically, however, they must be separated from the undifferentiated cell population to prevent teratoma formation. Efforts to purify neural stem/precursor cells from embryonic or adult brain, using cell surface markers or transgene expression driven by NP-specific promoters, have been reported (Keyoung *et al.* 2001; Rietze *et al.* 2001; Capela and Temple 2002; Murayama *et al.* 2002; Tamaki *et al.* 2002; Nagato *et al.* 2005). Of the markers that have been investigated, sox1 has shown the most specific expression pattern for NP populations during development (Pevny *et al.* 1998; Aubert *et al.* 2003; Pevny and Placzek 2005). Aubert and co-workers generated a sox1-GFP knock-in mouse and demonstrated that GFP expression overlaps well with endogenous sox1 expression, thus providing a good handle for purification of NPs using FACS. In addition to the embryonic or adult brain, ES cells represent another source of NP cells due to their unlimited proliferation capacity and their potential to generate most cell types *in vitro* (Lang *et al.* 2004a). Ying *et al.*, using sox1-GFP knock-in ES cells, demonstrated that differentiated ES cells expressing sox1-GFP acquired neuroepithelial morphology (Ying *et al.* 2003). Lang *et al.* (2004b) generated sox knock-in ES cells harboring the neomycin resistance gene, allowing enrichment of NPs by drug selection. These drug-selected ES cell-derived NP cells generated electrophysiologically functional neurons *in vitro*.

In this study, we used fluorescence-activated cell sorting (FACS) to purify ES cell-derived NPs using sox1-GFP knock-in reporter expression (Ying *et al.* 2003) and characterized them *in vitro* and *in vivo*. FACS purification of sox1-GFP⁺ cells efficiently yielded an enriched neural cell population while effectively removing teratoma-causing pluripotent cells. The resulting neural cell population can generate multiple subtypes of neural cells (Figs 4 and 6), demonstrating the value of these purified NPs as a tool for studying various neural cells *in vitro* and as a possible cell source for cell replacement therapy of various neurodegenerative diseases. In addition, we demonstrated that purifying NP prior to transplantation efficiently reduced tumor formation in the host brain. The heterogeneous nature of *in vitro*-differentiated ES cell preparations may raise concerns about their safe usage for therapeutic application and thus, it is essential to establish their safety before applying them to human diseases (Odorico *et al.* 2001). One way to prevent teratoma formation is to remove possible tumor-forming cells from the ES cell-derived neural cell preparation. We achieved this by using FACS purification of genetically marked ES cells.

The therapeutic use of ES cell-derived neural populations in animal models of various neurodegenerative diseases, such as intracerebral hemorrhage, Parkinson's disease, Huntington's disease, ischemia and myelin disease, has been reported (Dinsmore *et al.* 1996; Brustle *et al.* 1999; Kim *et al.* 2002;




Fig. 7 Transplantation analysis of FACS-purified cells. GFP⁺ and GFP⁻ cells were transplanted into mice striatum 4 days after FACS (NP stage), and the animals were killed 8 weeks after transplantation for histological analysis. Representative low power images of NeuN immunohistochemistry of grafts from GFP⁺ (a) and GFP⁻ (b) cells in naïve mouse striatum. TH immunohistochemistry on grafts from GFP⁺ cells using 20× objective (c; scale bar = 50 μm) and 63× objective (d; scale bar = 20 μm). (e) TH immunohistochemistry on contralateral side of the graft. Scale bar = 20 μm. (f) Total graft volume in GFP⁺ versus GFP⁻ grafts. ANOVA revealed $F = 18.457$, $p < 0.005$. Fisher's PLSD post-hoc analysis was performed with a significance level of

0.005; *indicates significant difference from GFP⁻ cells. (g) DA neuronal density expressed by DA neuronal number per mm³ graft volume in GFP⁺ versus GFP⁻ grafts. ANOVA revealed $F = 4.914$, $p < 0.05$. Fisher's PLSD post-hoc analysis was performed with a significance level of 0.05; *indicates significant difference from sox1-GFP⁻ cells. (h, i) Representative confocal images of SSEA1 immunohistochemistry in graft from GFP⁻ cells. Scale bar = 50 μm. (j, k) Representative confocal images of Ki67 immunohistochemistry in graft from GFP⁻ cells. Scale bar = 50 μm. (l-o) Representative confocal images of TH/DDC/DAT immunohistochemistry in grafts of GFP⁺ cells. Scale bar = 50 μm.

Barberi *et al.* 2003; Nonaka *et al.* 2004; Wei *et al.* 2005). Since the NPs purified in this study can be used to generate the various neural cells that are dying in these diseases, such as dopaminergic neurons, glutamatergic neurons and GABAergic neurons (Fig. 6; Lang *et al.* 2004b), the procedure described in this paper can be applied to these fields

with a high degree of confidence that potentially tumour-forming pluripotent stem cells can be removed prior to transplantation.

Another way to purify and prepare cells for transplantation is to isolate specific neuronal cell types from *in vitro*-differentiated ES cells rather than NPs. Zhao *et al.* generated

Pitx3 knock-in ES cells and purified midbrain dopaminergic neurons (Zhao *et al.* 2004). Transplantation of these cells has not been reported and thus, no evaluation of their safety and efficacy is available. Another group used the TH promoter to drive GFP expression, and transplanted the purified GFP⁺ cells into rat brain (Yoshizaki *et al.* 2004), but they reported very low graft survival. Unlike the NP population that we purified, mature neurons are more vulnerable to manipulations such as trypsination and FACS. When we transplanted FACS-sorted cells that had reached post-neuronal differentiation stages, we similarly observed lower graft survival compared with cells at the NP stage (data not shown). Thus, purification of specific types of neurons offers the advantage of a unique cell population for transplantation, whereas transplanting NPs has the advantage that these cells have better survival over the course of the manipulations. Additionally, in some cases, co-transplantation with astrocytes enhances neuronal differentiation and/or survival (Song *et al.* 2002; Dhandapani *et al.* 2003). By transplanting NPs that can generate both neurons and astrocytes (Fig. 6; Lang *et al.* 2004b), we may be able to achieve such a neuroprotective effect. Eventually, it will be even better if marker gene expression specific for each cell type can be used, and then single cell types can be purified and used alone or in combination for complete control of the phenotype of the cell being transplanted.

Using the five-stage procedure (Lee *et al.* 2000; Chung *et al.* 2002) to differentiate sox1-GFP ES cells, we have shown that some of the sox1-GFP⁺ cells express the early midbrain marker *Engrailed-1* and could generate DA neurons. We observed a rather low proportion of DA neurons being generated from sox1-GFP⁺ cells compared with the number generated from unsorted cells (Figs 1j–l and 5d–f). Interestingly, even though the GFP⁻ population generated far fewer neurons (Fig. 4), a majority of these neurons was dopaminergic (Fig. 5m; data not shown). We have postulated two explanations for this. First, it is possible that some NP cells that can generate DA neurons are not expressing sox1 and thus, are sox1-GFP⁻. Secondly, it is possible that there are DA-inducing, factor-releasing cells in the GFP⁻ populations. Our mixing experiment (Fig. 5m) supports the possibility that at least some of the DA precursors may be GFP⁻. Further studies will be needed to understand clearly this unexpected observation.

While we were preparing this manuscript, Fukuda *et al.* also reported reduction of teratoma formation by purification of ES-derived NPs using FACS (Fukuda *et al.* 2005). Using different methods of *in vitro* differentiation (PA6 co-culture procedure), they also showed enrichment of NPs and removal of pluripotent cells by FACS. Taken together, using two different *in vitro* differentiation methods, both studies demonstrate that NP cells derived from FACS purification of the sox1-GFP⁺ population can prevent tumor formation even 8 weeks post-transplantation. The PA6

co-culture procedure is less time-consuming and more efficient for DA differentiation than the five-stage method. However, the reason we used the five-stage procedure was so that we could compare the GFP⁺ versus GFP⁻ population without contaminating feeder cells. By using the five-stage procedure instead of the PA6 method, we could compare differentiation and proliferative potentials of GFP⁺ and GFP⁻ populations more clearly, which could not be done in the study of Fukuda *et al.* Thus, even though there are many advantages to using the PA6 system, we believe that the five-stage procedure is more beneficial for comparative studies of different cell populations. Furthermore, our study demonstrates that these purified NP cells can differentiate into various subtypes of neurons and glial cells and thus, can potentially be applied to various disease models. One striking difference in these two studies is the extremely small graft size generated by sox-GFP⁺ cells and the small number of DA neurons in the Fukuda *et al.* study, possibly because these cells were transplanted immediately after FACS. In contrast, we incorporated a recovery/expansion stage after FACS and before transplantation, resulting in increased graft size and more than 15-fold total DA neurons compared with their study. Taken together, whereas it can be a powerful method of removing unwanted cell types before transplantation, FACS could, at the same time, lower cell survival by imposing stress on the cells sorted. Our studies demonstrate that this pitfall can be largely resolved by providing for a recovery/expansion stage after FACS purification of the desired cell type.

Acknowledgements

This work was supported by Udall Parkinson's Disease Center of Excellence grants P50 NS39793, MH48866, DAMD-17-01-1-0762, DAMD 17-01-1-0763, the Post-doctoral Fellowship Program of Korea Science & Engineering Foundation (BSS) and the Swedish Brain Foundation (EH).

References

- Arnhold S., Klein H., Semkova I., Addicks K. and Schraermeyer U. (2004) Neurally selected embryonic stem cells induce tumor formation after long-term survival following engraftment into the subretinal space. *Invest. Ophthalmol. Vis. Sci.* **45**, 4251–4255.
- Aubert J., Stavridis M. P., Tweedie S. *et al.* (2003) Screening for mammalian neural genes via fluorescence-activated cell sorter purification of neural precursors from Sox1-gfp knock-in mice. *Proc. Natl Acad. Sci. USA* **100**, 11 836–11 841.
- Barberi T., Klivenyi P., Calingasan N. Y. *et al.* (2003) Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. *Nat. Biotechnol.* **21**, 1200–1207.
- Bjorklund L. M., Sanchez-Pernaute R., Chung S. *et al.* (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. *Proc. Natl Acad. Sci. USA* **99**, 2344–2349.

- Brustle O., Jones K. N., Learish R. D., Karram K., Choudhary K., Wiestler O. D., Duncan I. D. and McKay R. D. (1999) Embryonic stem cell-derived glial precursors: a source of myelinating transplants. *Science* **285**, 754–756.
- Bylund M., Andersson E., Novitsch B. G. and Muhr J. (2003) Vertebrate neurogenesis is counteracted by Sox1–3 activity. *Nat. Neurosci.* **6**, 1162–1168.
- Capela A. and Temple S. (2002) LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. *Neuron* **35**, 865–875.
- Chung S., Sonntag K. C., Andersson T., Bjorklund L. M., Park J. J., Kim D. W., Kang U. J., Isacson O. and Kim K. S. (2002) Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. *Eur. J. Neurosci.* **16**, 1829–1838.
- Deacon T., Dinsmore J., Costantini L. C., Ratliff J. and Isacson O. (1998) Blastula-stage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. *Exp. Neurol.* **149**, 28–41.
- Desbaillets I., Ziegler U., Groscurth P. and Gassmann M. (2000) Embryoid bodies: an *in vitro* model of mouse embryogenesis. *Exp. Physiol.* **85**, 645–651.
- Dhandapani K. M., Hadman M., De Sevilla L., Wade M. F., Mahesh V. B. and Brann D. W. (2003) Astrocyte protection of neurons: role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway. *J. Biol. Chem.* **278**, 43 329–43 339.
- Dinsmore J., Ratliff J., Deacon T., Pakzaban P., Jacoby D., Galpern W. and Isacson O. (1996) Embryonic stem cells differentiated *in vitro* as a novel source of cells for transplantation. *Cell Transplantation* **5**, 131–143.
- Evans M. J. and Kaufman M. H. (1981) Establishment in culture of pluripotential cells from mouse embryos. *Nature* **292**, 154–156.
- Fukuda H., Takahashi J., Watanabe K., Hayashi H., Morizane A., Koyanagi M., Sasai Y. and Hashimoto N. (2005) FACS-based purification of ES cell-derived neural precursors averts tumor formation after transplantation. *Stem Cells* (in press).
- Hooper M., Hardy K., Handyside A., Hunter S. and Monk M. (1987) HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. *Nature* **326**, 292–295.
- Johe K. K., Hazel T. G., Muller T., Dugich-Djordjevic M. M., McKay R. D., Vicario-Abejon C. and Collazo D. (1996) Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Functions of basic fibroblast growth factor and neurotrophins in the differentiation of hippocampal neurons. *Genes Dev.* **10**, 3129–3140.
- Kamachi Y., Uchikawa M. and Kondoh H. (2000) Pairing SOX off: with partners in the regulation of embryonic development. *Trends Genet.* **16**, 182–187.
- Keyoung H. M., Roy N. S., Benraiss A., Louissaint A., Jr, Suzuki A., Hashimoto M., Rashbaum W. K., Okano H. and Goldman S. A. (2001) High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain. *Nat. Biotechnol.* **19**, 843–850.
- Kim J. H., Auerbach J. M., Rodriguez-Gomez J. A. *et al.* (2002) Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. *Nature* **418**, 50–56.
- Lang K. J., Rathjen J., Vassilieva S. and Rathjen P. D. (2004a) Differentiation of embryonic stem cells to a neural fate: a route to re-building the nervous system? *J. Neurosci. Res.* **76**, 184–192.
- Lang R. J., Haynes J. M., Kelly J., Johnson J., Greenhalgh J., O'Brien C., Mulholland E. M., Baker L., Munsie M. and Pouton C. W. (2004b) Electrical and neurotransmitter activity of mature neurons derived from mouse embryonic stem cells by Sox-1 lineage selection and directed differentiation. *Eur. J. Neurosci.* **20**, 3209–3221.
- Lee S. H., Lumelsky N., Studer L., Auerbach J. M. and McKay R. D. (2000) Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. *Nat. Biotechnol.* **18**, 675–679.
- Lumelsky N., Blondel O., Laeng P., Velasco I., Ravin R. and McKay R. (2001) Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. *Science* **292**, 1389–1394.
- Martin G. R. (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc. Natl Acad. Sci. USA* **78**, 7634–7638.
- Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K., Maruyama M., Maeda M. and Yamanaka S. (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. *Cell* **113**, 631–642.
- Molofsky A. V., Pardal R., Iwashita T., Park I. K., Clarke M. F. and Morrison S. J. (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. *Nature* **425**, 962–967.
- Murayama A., Matsuzaki Y., Kawaguchi A., Shimazaki T. and Okano H. (2002) Flow cytometric analysis of neural stem cells in the developing and adult mouse brain. *J. Neurosci. Res.* **69**, 837–847.
- Nagato M., Heike T., Kato T., Yamanaka Y., Yoshimoto M., Shimazaki T., Okano H. and Nakahata T. (2005) Prospective characterization of neural stem cells by flow cytometry analysis using a combination of surface markers. *J. Neurosci. Res.* **80**, 456–466.
- Nagy A., Gozsa E., Diaz E. M., Pridoux V. R., Ivanyi E., Markkula M. and Rossant J. (1990) Embryonic stem cells alone are able to support fetal development in the mouse. *Development* **110**, 815–821.
- Nagy A., Rossant J., Nagy R., Abramow-Newerly W. and Roder J. C. (1993) Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. *Proc. Natl Acad. Sci. USA* **90**, 8424–8428.
- Nonaka M., Yoshikawa M., Nishimura F., Yokota H., Kimura H., Hirabayashi H., Nakase H., Ishizaka S., Wanaka A. and Sakaki T. (2004) Intraventricular transplantation of embryonic stem cell-derived neural stem cells in intracerebral hemorrhage rats. *Neurol. Res.* **26**, 265–272.
- Odorico J. S., Kaufman D. S. and Thomson J. A. (2001) Multilineage differentiation from human embryonic stem cell lines. *Stem Cells* **19**, 193–204.
- Okabe S., Forsberg-Nilsson K., Spiro A. C., Segal M. and McKay R. D. (1996) Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells *in vitro*. *Mech. Dev.* **59**, 89–102.
- Pevny L. and Placzek M. (2005) SOX genes and neural progenitor identity. *Curr. Opin. Neurobiol.* **15**, 7–13.
- Pevny L. H., Sockanathan S., Placzek M. and Lovell-Badge R. (1998) A role for SOX1 in neural determination. *Development* **125**, 1967–1978.
- Rietze R. L., Valcanis H., Brooker G. F., Thomas T., Voss A. K. and Bartlett P. F. (2001) Purification of a pluripotent neural stem cell from the adult mouse brain. *Nature* **412**, 736–739.
- Seaberg R. M. and van der Kooy D. (2003) Stem and progenitor cells: the premature desertion of rigorous definitions. *Trends Neurosci.* **26**, 125–131.
- Smith A. G. (1991) Culture and differentiation of embryonic stem cells. *J. Tiss. Cult. Meth.* **13**, 89–94.
- Song H., Stevens C. F. and Gage F. H. (2002) Astroglia induce neurogenesis from adult neural stem cells. *Nature* **417**, 39–44.
- Takahashi K., Mitsui K. and Yamanaka S. (2003) Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. *Nature* **423**, 541–545.
- Tamaki S., Eckert K., He D. *et al.* (2002) Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. *J. Neurosci. Res.* **69**, 976–986.

- Thomas K. R. and Capecchi M. R. (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. *Cell* **51**, 503–512.
- Uwanogho D., Rex M., Cartwright E. J., Pearl G., Healy C., Scotting P. J. and Sharpe P. T. (1995) Embryonic expression of the chicken Sox2, Sox3 and Sox11 genes suggests an interactive role in neuronal development. *Mech. Dev.* **49**, 23–36.
- Wachtel S. R., Bencsics C. and Kang U. J. (1997) Role of aromatic 1-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. *J. Neurochem.* **69**, 2055–2063.
- Wei L., Cui L., Snider B. J. *et al.* (2005) Transplantation of embryonic stem cells overexpressing Bcl-2 promotes functional recovery after transient cerebral ischemia. *Neurobiol. Dis.* **19**, 183–193.
- Wood H. B. and Episkopou V. (1999) Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pre-gastrulation to early somite stages. *Mech. Dev.* **86**, 197–201.
- Wutz A. and Jaenisch R. (2000) A shift from reversible to irreversible X inactivation is triggered during ES cell differentiation. *Mol. Cell* **5**, 695–705.
- Ying Q. L., Stavridis M., Griffiths D., Li M. and Smith A. (2003) Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. *Nat. Biotechnol.* **21**, 183–186.
- Yoshizaki T., Inaji M., Kouike H. *et al.* (2004) Isolation and transplantation of dopaminergic neurons generated from mouse embryonic stem cells. *Neurosci. Lett.* **363**, 33–37.
- Zhao S., Maxwell S., Jimenez-Beristain A., Vives J., Kuehner E., Zhao J., O'Brien C., de Felipe C., Semina E. and Li M. (2004) Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons. *Eur. J. Neurosci.* **19**, 1133–1140.